At present, the main treatment methods for RCC are: first-line combined treatment of metastatic RCC combined with immune checkpoint blocking, combining immune checkpoint blockade with tyrosine kinase inhibitors, and combination therapy with anti–vascular endothelial growth factor antibodies [6]. This evidence concerns the gene VEGFA and renal cell carcinoma.